Literature DB >> 14519049

Seizure potential of concomitant medications and radiographic contrast media agents.

Bethany A Fedutes1, Nicole T Ansani.   

Abstract

OBJECTIVE: To review seizure risk of concomitant medication administration and nonionic, water-soluble radiographic contrast media agents for myelography. DATA SOURCES: Clinical literature was identified through MEDLINE (1966-May 2003). Key search terms included metrizamide, iohexol, myelogram, myelography, seizure, and contraindications. DATA SYNTHESIS: Administration of myelography contrast media can produce rare serious adverse events, including meningeal irritation, seizures, or psychological disturbances. An evaluation of case reports and clinical trials concerning seizure risks of nonionic, water-soluble radiographic myelography contrast media and concomitant medications with potential to lower the seizure threshold was performed.
CONCLUSIONS: Available data supporting the incidence of increased seizure risk with nonionic, water-soluble contrast media agents and concomitant medication administration that lowers the seizure threshold are anecdotal. However, because of product labeling and additive potential to decrease the seizure threshold, discontinuation of such medications should be considered to avoid the presumed increased risk of seizures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519049     DOI: 10.1345/aph.1C464

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  2 in total

1.  It Is Not Necessary to Discontinue Seizure Threshold-Lowering Medications Prior to Myelography.

Authors:  M Krupa; H Salts; F Mihlon
Journal:  AJNR Am J Neuroradiol       Date:  2019-04-04       Impact factor: 3.825

2.  Inadvertent hyponatremia leading to acute cerebral edema and early evidence of herniation.

Authors:  Jessica Carpenter; Steve Weinstein; John Myseros; Gilbert Vezina; Michael J Bell
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.